NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of LAVA Therapeutics N.V. (NASDAQ: LVTX) to XOMA Royalty Corporation is fair to LAVA shareholders. Under the terms of the proposed transaction, XOMA Royalty will acquire LAVA for $1.16 in cash per share, plus up to $0.08 per share and a non-transferable contingent value right per share representing the right to receive 75% of the net proceeds related to LAVA’s two partnered assets and 75%
Related Questions
Is the proposed cash consideration of $1.16 per share plus contingent upside consistent with the intrinsic value of LAVA's assets?
How will the contingent value rights (CVR) affect the total effective transaction price and upside potential for current shareholders?
Could the transaction trigger any anti‑dilution provisions or warrant adjustments for existing shareholders?
What are the potential regulatory or legal risks associated with Halper Sadeh LLC’s investigation that could impact deal completion?
What is the expected impact of the transaction on LVTX stock liquidity and short‑term price volatility?
How might the sale impact LAVA's existing pipeline, partner relationships, and future cash flow forecasts?
What is the likelihood that the additional $0.08 per share and the CVR will be fully realized given XOMA Royalty's partnership assets performance?
What are the tax implications for shareholders receiving cash versus contingent value rights in this deal?
Does the proposed transaction represent a premium or discount relative to LAVA's recent trading range and valuation multiples?
Are there any comparable recent transactions in the biotech sector that can be used as benchmarks for assessing fairness?